GTBP
Price
$7.79
Change
-$1.21 (-13.44%)
Updated
Sep 16, 04:59 PM (EDT)
Capitalization
16.24M
Intraday BUY SELL Signals
XBIO
Price
$2.19
Change
-$2.08 (-48.71%)
Updated
Sep 16, 04:59 PM (EDT)
Capitalization
10.01M
51 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GTBP vs XBIO

GTBP vs XBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GTBP vs. XBIO commentary
Sep 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBP is a Hold and XBIO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GTBP($16.2M) has a higher market cap than XBIO($10M). XBIO YTD gains are higher at: 96.774 vs. GTBP (-54.152). XBIO has higher annual earnings (EBITDA): -2.64M vs. GTBP (-4.51M). XBIO has more cash in the bank: 6.47M vs. GTBP (4.96M). GTBP has less debt than XBIO: GTBP (0) vs XBIO (153K). XBIO has higher revenues than GTBP: XBIO (3.26M) vs GTBP (0).
GTBPXBIOGTBP / XBIO
Capitalization16.2M10M162%
EBITDA-4.51M-2.64M171%
Gain YTD-54.15296.774-56%
P/E Ratio0.07N/A-
Revenue03.26M-
Total Cash4.96M6.47M77%
Total Debt0153K-
FUNDAMENTALS RATINGS
GTBP vs XBIO: Fundamental Ratings
GTBP
XBIO
OUTLOOK RATING
1..100
234
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3836
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (18) in the Biotechnology industry is in the same range as GTBP (37) in the null industry. This means that XBIO’s stock grew similarly to GTBP’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that XBIO’s stock grew similarly to GTBP’s over the last 12 months.

XBIO's SMR Rating (98) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that XBIO’s stock grew similarly to GTBP’s over the last 12 months.

XBIO's Price Growth Rating (36) in the Biotechnology industry is in the same range as GTBP (38) in the null industry. This means that XBIO’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's P/E Growth Rating (19) in the null industry is significantly better than the same rating for XBIO (100) in the Biotechnology industry. This means that GTBP’s stock grew significantly faster than XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBPXBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
COMPARISON
Comparison
Sep 16, 2026
Stock price -- (GTBP: $9.00 vs. XBIO: $4.27)
Brand notoriety: GTBP and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GTBP: 47% vs. XBIO: 11%
Market capitalization -- GTBP: $16.24M vs. XBIO: $10.01M
GTBP [@Biotechnology] is valued at $16.24M. XBIO’s [@Biotechnology] market capitalization is $10.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBP’s FA Score shows that 1 FA rating(s) are green while XBIO’s FA Score has 1 green FA rating(s).

  • GTBP’s FA Score: 1 green, 4 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, GTBP is a better buy in the long-term than XBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBP’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 5 bullish TA indicator(s).

  • GTBP’s TA Score: 4 bullish, 7 bearish.
  • XBIO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XBIO is a better buy in the short-term than GTBP.

Price Growth

GTBP (@Biotechnology) experienced а +71.43% price change this week, while XBIO (@Biotechnology) price change was -0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.89%. For the same industry, the average monthly price growth was -6.85%, and the average quarterly price growth was +5.11%.

Reported Earning Dates

XBIO is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GTBP
Daily Signal:
Gain/Loss:
XBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLSM2.41-0.01
-0.41%
Pulsenmore Ltd.
PSN46.65-0.29
-0.62%
Parsons Corp
AON304.67-6.87
-2.21%
Aon plc
SVCO6.32-0.15
-2.32%
Silvaco Group Inc
UPBD17.75-0.50
-2.74%
Upbound Group

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with SLGL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then SLGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
-22.61%
SLGL - GTBP
33%
Loosely correlated
-1.20%
AMRN - GTBP
33%
Poorly correlated
-0.50%
MDGL - GTBP
32%
Poorly correlated
-3.11%
VKTX - GTBP
31%
Poorly correlated
-5.01%
XBIO - GTBP
29%
Poorly correlated
-1.39%
More

XBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBIO has been loosely correlated with ELOX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIO jumps, then ELOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-1.39%
ELOX - XBIO
59%
Loosely correlated
+11.96%
ACXP - XBIO
38%
Loosely correlated
-2.16%
XTLB - XBIO
35%
Loosely correlated
-4.17%
TCRT - XBIO
34%
Loosely correlated
-3.42%
NERV - XBIO
33%
Loosely correlated
-4.49%
More